Soiken Holdings Inc. (2385) AI Stock Analysis

• Market Cap: ¥6.23B
• Dividend Yield: 2.08%
• Average Volume (3M): 187.76K
• Price to Earnings (P/E): 19.7
• Beta (1Y): 0.86
• Revenue Growth: -10.24%
• EPS Growth: N/A
• Country: JP
• Employees: 90
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 26,158,200
• 10 Day Avg. Volume: 461,280
• 30 Day Avg. Volume: 187,763
• PEG Ratio: 0.31
• Price to Book (P/B): 0.73
• Price to Sales (P/S): 0.91
• P/FCF Ratio: 8.43
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: ¥269.00 ▲(13.98% Upside)
• Action: Reiterated Date: 12/30/25
• Date: Action: Reiterated 12/30/25

The score is held back primarily by deteriorated profitability and declining revenue despite a strong, debt-free balance sheet and improving (but still volatile) cash flow. Technicals are moderately supportive with price above key longer-term moving averages, while valuation is a notable drag due to a high P/E that is hard to support given the recent earnings weakness.

Positive Factors

Debt-free balance sheet

The company’s debt-free balance sheet and substantial equity materially reduce financial risk and provide strategic flexibility. Over the next 2–6 months this supports funding for R&D, product development or working-capital needs without reliance on external debt, stabilizing operations while profits recover.

Return to positive cash flow (2025)

Positive operating and free cash flow in 2025 signals improved cash discipline and lowers near-term funding risk. If sustained, this enables self-funding of operations and targeted investments, reduces dilution risk, and improves resilience through typical biotech funding cycles and development timelines.

High gross margins

Stable gross margins near 50% provide structural profit potential if revenue stabilizes. High gross margins indicate pricing power or efficient production, allowing operating leverage to drive margin recovery faster as sales recover or fixed costs are optimized, supporting longer-term profitability.

Negative Factors

Deteriorated profitability

Swinging to net losses in 2024–2025 shows profitability has deteriorated materially. Persistent negative margins erode equity, constrain reinvestment and hiring, and raise the bar for recovery; management must restore sustainable operating profit to avoid recurring funding or strategic compromises.

Declining revenue trend

Multi-year revenue decline (negative growth in 2023–2025) signals weakening demand or execution issues. Prolonged top-line shrinkage undermines scale economies, reduces headroom for fixed-cost absorption, and makes margin recovery and durable profitability harder without product, commercial or market inflection.

Volatile cash generation

Cash generation has been uneven, creating unpredictability in funding operations and investments. This volatility increases execution risk, complicates multi-year planning and capital allocation, and could force dilutive financing or project delays if the positive 2025 cash outcome does not persist.

Soiken Holdings Inc. Business Overview & Revenue Model

Company Description

Soiken Holdings Inc. engages in the development of biomarkers in Japan. The company is involved in the development and sale of cosmetics and dietary supplements; licensing and development of biomarker technology; provision of marketing research and post-marketing surveys for dietary supplements; and research, development, and sale of functional materials, such as lactoferrin, as well as pharmaceutical products from ascochlorin derivatives. It also provides clinical evaluation tests for foodstuffs using biomarker technology; support for physician-led pharmaceutical clinical research, health checkups, and specific health guidance; and services to health insurance societies, including contracted health guidance, specific health checkup promotion services for the dependents of insured, and service to prevent diabetes. Soiken Holdings Inc. was incorporated in 1994 and is headquartered in Toyonaka, Japan.

How the Company Makes Money

Soiken Holdings Inc. generates revenue through a multi-faceted business model centered around its healthcare and pharmaceutical services. The company earns income from the development and sale of health supplements and functional foods, which are distributed through various retail and online channels. Additionally, it provides healthcare consulting services, which contribute to its revenue streams. Partnerships with other healthcare companies and institutions play a significant role in expanding its market reach and enhancing its product offerings, thereby increasing its earnings potential.

Soiken Holdings Inc. Financial Statement Overview

Summary

Financials are mixed: profitability and revenue have weakened with net losses in 2024–2025 and declining revenue, but the balance sheet is strong with no debt and substantial equity. Cash flow improved in 2025 (positive operating cash flow/free cash flow) after volatility in prior years, reducing near-term funding risk but leaving execution risk around restoring sustainable profits.

Income Statement

Profitability has deteriorated materially: after solid operating and net profits in 2020–2023, the company swung to losses in 2024 and remained loss-making in 2025 (annual). While gross margin stayed relatively stable around the high-40% to ~50% range, operating margin turned negative and net margin was modestly negative in 2025 after a much larger loss in 2024—showing some improvement, but still below breakeven. Revenue is also trending down over the last three years (negative growth in 2023–2025), which raises concerns about near-term earnings recovery.

Balance Sheet

The balance sheet is conservatively positioned with no debt reported across all periods, which meaningfully reduces financial risk and provides flexibility. Equity remains substantial relative to assets, supporting overall stability. The main weakness is profitability-driven: returns on equity have turned negative in 2024–2025 after being healthy in 2020–2023, indicating the company is currently not generating acceptable returns on its capital base.

Cash Flow

Cash generation is mixed and somewhat volatile. The company produced strong positive operating cash flow and free cash flow in 2022, but cash flow was negative in 2021 and 2023 and fell sharply in 2024. Encouragingly, 2025 returned to positive operating cash flow and free cash flow, suggesting improving cash discipline or working-capital timing. However, the uneven pattern year-to-year limits confidence in the durability of cash generation.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	4.85B	5.16B	8.08B	9.35B	8.94B
Gross Profit	2.41B	2.48B	3.72B	4.26B	4.11B
EBITDA	-201.93M	-583.21M	750.07M	1.23B	948.13M
Net Income	-210.70M	-662.20M	451.85M	809.71M	562.06M
Balance Sheet
Total Assets	6.81B	6.96B	8.24B	8.49B	7.15B
Cash, Cash Equivalents and Short-Term Investments	5.26B	4.79B	5.95B	6.22B	4.26B
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	775.16M	708.58M	1.07B	1.64B	915.00M
Stockholders Equity	6.02B	6.23B	6.97B	6.65B	6.04B
Cash Flow
Free Cash Flow	521.19M	-895.42M	-141.08M	2.09B	-131.65M
Operating Cash Flow	557.96M	-880.82M	-101.55M	2.14B	-107.44M
Investing Cash Flow	-389.41M	-14.29M	160.37M	-244.58M	-24.85M
Financing Cash Flow	-214.00K	-260.71M	-130.21M	-129.94M	-131.25M

Soiken Holdings Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 236.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2385, the sentiment is Positive. The current price of 236 is below the 20-day moving average (MA) of 251.70, below the 50-day MA of 253.14, and above the 200-day MA of 208.35, indicating a neutral trend. The MACD of -2.90 indicates Positive momentum. The RSI at 47.98 is Neutral, neither overbought nor oversold. The STOCH value of 43.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2385.

Soiken Holdings Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2385	58 Neutral	¥6.23B	19.71	―	2.08%	-10.24%	―
2342	56 Neutral	¥4.59B	-828.32	―	―	-0.77%	-288.43%
2183	52 Neutral	¥6.32B	-2.65	―	5.44%	-15.42%	-879.08%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
206A	48 Neutral	¥6.69B	-5.04	―	―	―	―
2370	46 Neutral	¥8.27B	-5.66	―	―	5.44%	-2.17%
4891	45 Neutral	¥6.46B	―	―	―	―	―